Moderna announced the results of phase II and III clinical trials of the COVID-19 vaccine in the under-18 age group, where the US company claimed the vaccine remained 100% effective for these ages. The Moderna COVID-19 vaccine is currently approved for use in individuals aged 18 and above.
The Moderna vaccine has been reported to provide 93% protection against COVID-19 after the first dose and 100% protection after the second boost dose in children aged 12 to 17 years.
Phase II and III clinical trials involving more than 3,700 adolescents reported no major safety concerns.
The most common side effect after the first dose is pain at the injection site. The most common side effects after the second dose are headache, fatigue, muscle aches and tremors.
All clinical trial participants will be monitored over the next 12 months to determine the long-term protection and safety of the Moderna COVID-19 vaccine.
Calling the results to conduct clinical trials, Stephane Bancel, Moderna CEO, said the company will now submit these results to the US Food and Drug Administration (FDA) and other international regulatory agencies early next month to seek approval for age group 12 to 17.
Latest posts by News Desk (see all)
- FBR asked to enhance efforts for Broadening Tax Net - May 27, 2023
- National Savings Rate for June-2023 - May 27, 2023
- Islamabad to get a new “Luxury Resort” - May 27, 2023
